Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS)(UG3/UH3 Clinical Trial Required)
Closed Posted
- Opportunity number
- RFA-CA-19-018
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Categories
-
- Education
- Health
- Eligible applicants
-
- 501(c)(3) Nonprofits
- Tribal Governments (Federally Recognized)
- Higher Education Inst. (Private)
- Other
- State Governments
- Tribal Organizations (Not Federally Recognized)
- For Profit Organizations
- City/Township Governments
- Higher Education Inst. (Public)
- Independent School Districts
- County Governments
- Public or Indian Housing Auth.
- Small Businesses
- Special District Governments
- Non-501(c)(3) Nonprofits
- Full announcement
Opportunity details come from Grants.gov. Updated .
Synopsis
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. This purpose of this FOA is to promote research in colorectal cancer (CRC) screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based approaches. The Accelerating Colorectal Cancer Screening and Follow-up through Implementation Science (ACCSIS) program will provide an evidence base for multilevel interventions that increase rates of CRC screening, follow-up, and referral-to-care, and best practices for how multilevel interventions can be scaled-up to reduce the burden of colorectal cancer on the United States (U.S.) population. The UG3/UH3 projects in response to this FOA must apply for both the UG3 and UH3 phases together in the single application. The UG3 effort is to be used for the development of one-year, milestone-driven planning phase (UG3), with possible rapid transition to the second phase (UH3) for clinical trials. UH3s will be awarded after administrative review of eligible UG3s that have met the scientific milestones and feasibility requirements necessary for the UH3 phase, depending on availability of funds.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Files
| File | Type | Posted |
|---|---|---|
| PKG00246013-instructions.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity